This is a working overview of Synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-27 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
For services to the community in Ross-on-Wye, Herefordshire. Sylvia Joan West. For services to the community in County Down. The Venerable Thomas Roderic West. Minister, Church of Ireland. For services to the community in County Down. David Wheeler. Chair, Lisnaskea Rovers Football Club. For services to Association Football in County Fermanagh. Martin John White. For services to Music in Northern Ireland. Dorothy Margaret Whittington. Volunteer, Oxford University Newcomers. For services to Volunteering and Higher Education. Gwendoline Ann Wickham. President, Guild of the Royal Hospital of St Bartholomew. For services to Charity and to the community in London. Dr Jane Wilcock. Chair, North West Faculty, Royal College of General Practitioners and lately General Practitioner, Silverdale Medical Practice, Swinton, Greater Manchester. For services to General Practice. Martin Peter Wild. For services to the community in Tamworth, Staffordshire. Jonathan Peter Willcocks. Musical Director, The Chichester Singers. For services to Music. Matthew James Willer. Founder, The Papillon Project. For services to Young People. Goodeson Lloyd Williams. For services to the community in the London Borough of Enfield during Covid-19. Howard Mansell Williams. For services to the Royal British Legion and to the community in Spondon, Derbyshire. Joan Barbara Williams. Diary Manager, Minister of State for Industry and Economic Security, Department for Business and Trade. For Public Service. Linda Elaine Williams. Volunteer Support Administrator, Welsh Ambulance Services NHS Trust.
==== Using difference between detrital zircons crystallisation ages and their corresponding maximum depositional age ==== Apart from the detrital zircon age abundance, difference between detrital zircons crystallisation ages (CA) and their corresponding maximum depositional age (DA) can be plotted in cumulative distribution function to correlate particular tectonic regime in the past. The effect of different tectonic settings on the difference between CA and DA is illustrated in Figure 7 and summarized in Table. 3.
==== Estrogenic and antiestrogenic activities ==== CPA does not bind to the estrogen receptors. Accordingly, pre-treatment with CPA does not block the retention of estradiol in the brain in mice. CPA has no estrogenic or direct antiestrogenic activity. However, CPA has been reported to produce weak estrogenic effects in rodents. In any case, CPA has prominent indirect antiestrogenic effects via its progestogenic activity. This includes PR-mediated antiestrogenic activity in certain tissues like the uterus and vagina as well as suppression of estrogen levels via its PR-mediated antigonadotropic activity. CPA also has indirect estrogenic activity in the breasts via its antiandrogenic activity, as androgens have strong functional antiestrogenic effects in this part of the body. This underlies the slight gynecomastia that can occur with CPA in men.
Nick Coatsworth is an Australian infectious diseases expert. He was Australia's deputy chief medical officer during the early years of the COVID-19 pandemic, when he regularly appeared in print and on radio and television to provide the public with information. He is Nine Network's medical expert and presents the television show Do You Want to Live Forever? with Tracy Grimshaw.
Sources: en.wikipedia.org
Briton Callum Tindal-Draper is killed while fighting with the 4th International Legion in Ukraine. 6 November – At Newcastle Crown Court, former GP Thomas Kwan is sentenced to 31 years in prison after posing as a community nurse to inject his mother's partner with a substance that caused him to contract a flesh eating disease following a row over inheritance. 7 November The Bank of England cuts the UK interest rate by 0.25% to 4.75%, but indicates further cuts may take longer than previously thought following the October budget, which it forecasts will lead to price increases. Argentinian authorities announce that three people have been charged in connection with the death of One Direction's Liam Payne. A report into more than 100 allegations of sexual abuse against barrister John Smyth QC, who died in 2018, finds his activities were covered up by the Church of England for several decades. Smyth used his home as a Christian summer camp during the 1970s and 1980s, when the abuse of boys and young men is thought to have happened. The Football Association opens a safeguarding inquiry into a Premiership club official following sexual allegations made by three women. The charity organisation Care England estimates that as a result of the increase in employers' National Insurance contributions and the national minimum wage in the recent budget, that the cost of providing care will increase by over £3,000 per person and that the increases are expected to be passed on to care home residents and their relatives.
== Origins of pathology == Early understanding of the origins of diseases constitutes the earliest application of the scientific method to the field of medicine, a development which occurred in the Middle East during the Islamic Golden Age and in Western Europe during the Italian Renaissance. The Greek physician Hippocrates, the founder of scientific medicine, was the first to deal with the anatomy and the pathology of human spine. Galen developed an interest in anatomy from his studies of Herophilus and Erasistratus. The concept of studying disease through the methodical dissection and examination of diseased bodies, organs, and tissues may seem obvious today, but there are few if any recorded examples of true autopsies performed prior to the second millennium. Though the pathology of contagion was understood by Muslim physicians since the time of Avicenna (980–1037) who described it in The Canon of Medicine (c. 1020), the first physician known to have made postmortem dissections was the Arabian physician Avenzoar (1091–1161) who proved that the skin disease scabies was caused by a parasite, followed by Ibn al-Nafis (b. 1213) who used dissection to discover pulmonary circulation in 1242. In the 15th century, anatomic dissection was repeatedly used by the Italian physician Antonio Benivieni (1443–1502) to determine cause of death. Antonio Benivieni is also credited with having introduced necropsy to the medical field. Perhaps the most famous early gross pathologist was Giovanni Morgagni (1682–1771).
The Francis Crick Institute "Francis Harry Compton Crick (1916–2004)" by A. Andrei at the Embryo Project Encyclopedia Francis Crick on Nobelprize.org Portraits of Francis Crick at the National Portrait Gallery, London Crick papers
Sources: en.wikipedia.org
ASH1L (also called huASH1, ASH1, ASH1L1, ASH1-like, or KMT2H) is a histone-lysine N-methyltransferase enzyme encoded by the ASH1L gene located at chromosomal band 1q22. ASH1L is the human homolog of Drosophila Ash1 (absent, small, or homeotic-like). Ash1 was discovered as a gene causing an imaginal disc mutant phenotype in Drosophila. Ash1 is a member of the trithorax-group (trxG) of proteins, a group of transcriptional activators that are involved in regulating Hox gene expression and body segment identity. Drosophila Ash1 interacts with trithorax to regulate ultrabithorax expression. The human ASH1L gene spans 227.5 kb on chromosome 1, band q22. This region is rearranged in a variety of human cancers such as leukemia, non-Hodgkin's lymphoma, and some solid tumors. The gene is expressed in multiple tissues, with highest levels in brain, kidney, and heart, as a 10.5-kb mRNA transcript. Mutations in ASH1L in humans have been associated with autism, epilepsy, and intellectual disability.
The only stable yttrium isotope, 89Y, will be found with yield somewhat less than 1% in a fission product mixture which has been allowed to age for months or years, as the next-longest lived yttrium isotopes have half-lives of only 107 days (88Y) or 59 days (91Y). However, a small amount of yttrium-90 will be found in secular equilibrium with its parent strontium-90 unless the two elements are separated from each other. 90Sr decays into 90Y which is a beta emitter with a half-life of 2.67 days. 90Y is sometimes used for medical purposes and can be obtained either by the neutron activation of stable 89Y or by using a device similar to a technetium cow. As the half-lives of the unstable yttrium isotopes are low (88Y being the longest at 106 days), yttrium extracted from strontium-free moderately aged spent fuel has negligible radioactivity. However, the strong gamma emitter 90Y will be present as long as its parent nuclide 90Sr is. Should a nonradioactive sample of yttrium be desired, care must be taken to remove all traces of strontium and sufficient time to let the short lived Y-90 (64 hours half-life) decay must be allowed before the product can be used.
Promising results of health and medical research are reported: further evidence that breastfeeding is important for the cognitive child development due to its unique ingredients (11 July), trialed hydroxyapatite toothpaste – which can also include fluoride in addition – against caries (18 July), gene therapy eyedrops of Vyjuvek, which was approved in May, against blindness (24 July), the second release from the global WikiGuidelines, a practically oriented guideline on the diagnosis and management of infective endocarditis, demonstrates a novel approach that incorporates uncertainties more than conventional guideline reviews (31 July).
== Bone balance == Acidosis inhibits bone osteoblast matrix mineralization with reciprocal effect on osteoclast activation. The combined responses of these cells to acidosis maximizes the availability of hydroxyl ions in solution that can be used to buffer protons. The utilization of bone to buffer even a small percentage of daily acid production can lead to significant loss of bone mass in the course of a decade. Additionally, as the body ages there is a steady decline in renal function. Metabolic acidosis can become more severe as kidney function weakens, and the body will depend more heavily on bone and blood to maintain acid-base homeostasis.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.